Author: Nichols Martin|| Date Published: September 28, 2018
The Food and Drug Administration has awarded four companies contracts worth up to $75M each to develop automated methods for reporting adverse drug events.
IBM (NYSE: IBM), Acumen, Dovel Technologiesand IQVIA Government Solutions will use artificial intelligence, machine learning, natural language processing and other automation techniques to create data collection and analysis systems for the FDA’s Center for Biologics Evaluation and Research, the agency said Thursday in a FedBizOpps notice.
FDA requires each contractor to offer indirect access to medical information of U.S. patients, including administrative and claims data and electronic health records.
The indefinite delivery/indefinite quantity contracts have a five-year ordering period.
The agency also selected the four companies to develop surveillance tools as part of the Biologics Effectiveness and Safety Initiative.
Lockheed Martin will add Ultra Maritime’s sonar, sonobuoys, torpedo defense and autonomous maritime sensing capabilities Ultra Maritime’s portfolio will strengthen…
Army Comptroller Marc Andersen has called for scaling private capital to strengthen national security Army installations can support industrial growth,…
The Food and Drug Administration has awarded four companies contracts worth up to $75M each to develop automated methods for reporting adverse drug events.
